Prelude Therapeutics Inc (PRLD)股票已触及新的52周低点，交易价格为1.1美元，该公司正面临充满挑战的市场环境。这一最新价格标志着这家生物制药公司的重大下跌，过去一年其股票价值下降了65%。投资者正密切关注PRLD的表现，因为该公司正在经历一段波动期，并寻求在竞争激烈的生物科技板块重新站稳脚跟。52周低点成为该公司短期前景和潜在战略调整的关键指标。

Prelude Therapeutics Incorporated (PRLD) has been on a downward spiral lately with significant selling pressure. After ...

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...

HC Wainwright & Co.：重申Prelude Therapeutics(PRLD.US)评级，由买入调整至买入评级, 目标价由5.00美元调整至5.00美元。 Prelude Therapeutics（PRLD.US）公司简介 ...

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorpora PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session ...

Prelude Therapeutics Inc (NASDAQ:PRLD), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, finds itself at a critical juncture as it ...

Prelude Therapeutics ( (PRLD) ) has provided an announcement. Prelude Therapeutics announced its third quarter 2024 financial results, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Barclays analyst Peter Lawson lowered the firm’s price target on Prelude Therapeutics (PRLD) to $1 from $3 and keeps an Underweight rating on the shares. The updated SMARCA2 degrader data show ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the third quarter ended ...